Jay D. Horton

Surgery · 2002–2020

A researcher in the Science corpus: 16 papers; trusts 5 researchers and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

• Surgery — 128 citations into it; #253 of 1,106 by trust here, #54 by citations
• Molecular Biology — 81 citations into it; #7,551 of 17,773 by trust here, #2,765 by citations
• Epidemiology — 46 citations into it; #991 of 2,148 by trust here, #303 by citations
• Oncology — 18 citations into it; #713 of 1,698 by trust here, #317 by citations

Whom Jay D. Horton trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Jonathan C. Cohen
2. P. Cohen

Who trusts Jay D. Horton overall

1. J. Goldstein
2. Michael S. Brown
3. Y. Kawano
4. J. Y. Chiang
5. Tiangang Li
6. M. Laplante
7. M. Mbikay
8. Timothy R. Peterson
9. Manabu T. Nakamura
10. Jonathan C. Cohen

Papers from Jay D. Horton's perspective

Ordered by how strongly the researchers Jay D. Horton trusts endorse each paper. Same corpus, a different order for every researcher.

1. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
2. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. (Molecules and Cells)
3. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 (Nature Genetics)
4. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption (Nature Genetics)
5. Newly identified loci that influence lipid concentrations and risk of coronary artery disease (Nature Genetics)
6. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (Proceedings of the National Academy of Sciences of the United States of America)
7. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* (Journal of Biological Chemistry)
8. Molecular biology of PCSK9: its role in LDL metabolism. (TIBS -Trends in Biochemical Sciences. Regular ed)
9. Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 (Journal of Lipid Research)
10. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

Their papers

• Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes (2003) — 1,475 citations
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. (2005) — 725 citations
• SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. (2002) — 5,004 citations
• Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c* (2002) — 663 citations
• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (2008) — 660 citations
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. (2006) — 659 citations
• Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* (2007) — 782 citations
• Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) — 1,302 citations
• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) — 3,303 citations
• Human Fatty Liver Disease: Old Questions and New Insights (2011) — 2,072 citations
• PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008. (2009) — 613 citations
• Molecular biology of PCSK9: its role in LDL metabolism. (2007) — 613 citations
• Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. (2006) — 715 citations
• Molecular mediators of hepatic steatosis and liver injury. (2004) — 2,066 citations
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity (2004) — 3,736 citations
• Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. (2002) — 732 citations